Based on your answers, here is information about starting HER2-targeted therapy.
As you read your results, look out for underlined words that you can click on to see the term defined.
Your doctor may recommend one of the following:
People with HER2+, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive).
PERJETA is given with another HER2‑targeted treatment called Herceptin® (trastuzumab) and chemotherapy. PERJETA and Herceptin are intravenous (IV) infusions that are given back-to-back in about 1-2.5 hours.*
PHESGO brings together PERJETA and Herceptin in a single injection just under the skin. It is given with chemotherapy. The first dose of PHESGO takes about 8 minutes. After that, receiving PHESGO takes about 5 minutes.*
*This does not account for observation time and other aspects of treatment. Actual clinic time may vary.
Remember, this site is for educational purposes only. Your primary sources of information should always be your doctor and the professionals who make up your healthcare team. Only they can give you medical advice about HER2+ early breast cancer and treatment.
Both PERJETA and Herceptin are HER2-targeted therapies that work alongside chemotherapy to treat HER2+ breast cancer.
417 people with certain types of HER2+ early breast cancer receiving treatment before surgery (neoadjuvant treatment).
To see if people who received PERJETA + Herceptin + chemotherapy treatment before surgery (neoadjuvant) were more likely to have no detectable cancer cells after surgery.
Almost twice as many people who got PERJETA + Herceptin before surgery had no detectable cancer cells in the lymph nodes and breast tissue removed during surgery, compared with people who got the other treatment.
What are the most serious side effects of PERJETA?
What are other possible serious side effects of PERJETA?
PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA. Possible serious and sometimes fatal side effects of PERJETA include infusion-related reactions and severe allergic reactions (hypersensitivity reactions/anaphylaxis).
See additional Important Safety Information below.
The dosing schedule for PERJETA is organized by cycle. For example, PERJETA is given once every 3 weeks. That is 1 cycle.
People who are eligible may receive 3-6 cycles (9-18 weeks) of PERJETA and Herceptin before surgery, unless side effects cause the treatment to be stopped sooner. You will also be given chemotherapy, but the dosing schedule and number of cycles will depend on which type of chemotherapy you receive.
PHESGO—a combination with PERJETA and Herceptin in a single ~5 minute injection under the skin.* PHESGO is given as part of a complete treatment regimen for HER2+ breast cancer that includes chemotherapy.
If you’re receiving PERJETA + Herceptin, your doctor may be able to switch you to PHESGO if they think it’s right for you.
*Your first dose is given in ~8 minutes. This does not account for observation time and other aspects of treatment. Actual clinic time may vary.
500 people with certain types of HER2+ early breast cancer.
To find out if there were any differences between PHESGO and PERJETA + Herceptin.
The study measured the amount of medicine in the bloodstream, which is commonly done to check that the injection works like the infusion. The study also looked at how safe the drug was and if it worked on the cancer.
No major difference was seen in the amount of medicine that went into the bloodstream with PHESGO compared to PERJETA + Herceptin.
The combined results of the study showed no major difference is expected in how PHESGO works.
160 people with certain types of HER2+ early breast cancer.
To find out if people preferred one treatment over the other.
All participants were given IV PERJETA + Herceptin + chemotherapy before surgery. After surgery, some were given 3 cycles of IV PERJETA + Herceptin then 3 cycles of PHESGO. Others were given PHESGO first then IV PERJETA + Herceptin. Everyone completed a total of 18 cycles of treatment. Patients were asked which treatment they preferred after they completed 6 cycles.
More people preferred PHESGO over PERJETA + Herceptin
The most common reason people preferred PHESGO was because it took less time in the clinic.
The most common reason people preferred IV PERJETA + Herceptin was because it felt more comfortable during administration.
What are the most serious side effects of PHESGO?
Who should not receive PHESGO?
PHESGO should not be used in patients who are allergic to pertuzumab, trastuzumab, hyaluronidase, or to any of the ingredients in PHESGO.
What are other possible serious side effects?
See additional Important Safety Information below.
The dosing schedule for PHESGO is organized by cycle. For example, PHESGO is given once every 3 weeks. That is 1 cycle.
People who are eligible may receive 3-6 cycles (9-18 weeks) of PHESGO before surgery, unless side effects cause the treatment to be stopped sooner. You will also be given chemotherapy, but the dosing schedule and number of cycles will depend on which type of chemotherapy you receive.
PERJETA + Herceptin |
PHESGO |
|
---|---|---|
What active ingredients are in the treatment? |
Pertuzumab |
Pertuzumab |
How does one receive treatment? |
Intravenous (IV) infusion, given by a healthcare provider |
Subcutaneous (under the skin) injection, given by a healthcare provider |
How much time will it take to receive treatment? |
About 1-2.5 hours:
This does not account for observation time and other aspects of treatment. Actual clinic time may vary. |
Your first dose is given in about 8 minutes. Other injections take about 5 minutes. This does not account for observation time and other aspects of treatment. Actual clinic time may vary. |
How do these treatments compare? |
A study comparing PHESGO to PERJETA + Herceptin found no major difference is expected in how well PHESGO works. By taking PHESGO, you're taking the same medicines, just in less time. |
|
What about side effects? |
There are side effects associated with both treatments. The comparison study did not find any significant difference between the 2 treatments. |
As you read your results, look out for underlined words that you can click on to see the term defined.
We want to help provide you with the information you need to feel empowered throughout your treatment for HER2+ EBC.
Here are some starter questions to begin a conversation with your doctor or healthcare team:
What does PERJETA treat?
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin® (trastuzumab) and chemotherapy for:
Important Safety Information
Side effects may vary based on chemotherapy regimen.
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Talk to a healthcare professional for more information about the benefits and risks of PERJETA.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
What does PHESGO treat?
PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for:
Important Safety Information
What are the most common side effects?
The most common side effects of PHESGO when given with chemotherapy as part of an early breast cancer regimen are:
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Talk to a healthcare professional for more information about the benefits and risks of PHESGO.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
Who is KADCYLA for?
Early Breast Cancer
KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including taxane and trastuzumab (Herceptin®) and there is cancer remaining in the tissue removed during surgery. Patients are selected for therapy based on an FDA-approved test for KADCYLA.
Important Safety Information
What is the most Important Safety Information I should know about KADCYLA?
Liver problems
Heart problems
Pregnancy
Contact your doctor right away if you experience symptoms associated with these side effects.
What are the additional possible serious side effects of KADCYLA?
Lung problems
Infusion-related reactions
Serious bleeding
Low platelet count
Nerve damage
Skin reactions around the infusion site
What are the most common side effects of KADCYLA?
The most common side effects in people taking KADCYLA for early breast cancer are:
You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555. You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
Talk to a healthcare professional for more information about the benefits and risks of KADCYLA.
Please see full Prescribing Information for Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
What does PERJETA treat?
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin® (trastuzumab) and chemotherapy for:
Important Safety Information
Side effects may vary based on chemotherapy regimen.
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Talk to a healthcare professional for more information about the benefits and risks of PERJETA.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.